CDKN2A and cancer: In addition, gliomas (Spyropoulou et al., 2014), hepatocellular carcinoma (Wong et al., 2016), nasopharyngeal carcinoma (Huang et al., 2018), solid tumors (Richter et al., 2009), and lung cancer (Rodriguez-Paredes et al., 2014) have been observed to decrease the viability and wound-healing ability of SETDB1 knockdown HNC cells in various cancer types, which is in parallel with studies reporting suppressed SETDB1 expression with siRNA; P16-INK4A is a tumor suppressor protein that plays a role in cell cycle regulation (Wang et al., 2003).